W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 31.7 HKD Market Closed
Market Cap: 38B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

WuXi XDC Cayman Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi XDC Cayman Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
W
WuXi XDC Cayman Inc
HKEX:2268
Cash from Financing Activities
ÂĄ3.5B
CAGR 3-Years
271%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash from Financing Activities
-ÂĄ6.5B
CAGR 3-Years
-50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash from Financing Activities
-ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash from Financing Activities
ÂĄ673.6m
CAGR 3-Years
-66%
CAGR 5-Years
133%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash from Financing Activities
-ÂĄ754.7m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Cash from Financing Activities
-ÂĄ60m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
38B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc. is an intriguing player in the biotechnology field, strategically positioned at the crossroads of innovation and precision. As a distinctive subsidiary under the umbrella of WuXi AppTec, it zeroes in on the burgeoning and highly specialized market of antibody-drug conjugates (ADCs). These ADCs are engineered to deliver chemotherapy drugs directly to cancer cells, offering a synthesis of traditional medicine's effectiveness with the pinpoint accuracy of modern biotechnology. This localized delivery aims to enhance therapeutic outcomes while minimizing adverse effects, a compelling value proposition amid rising consumer demand for more personalized cancer treatments. The company thrives through an integrated business model, presenting a suite of comprehensive services that span the entire ADC development lifecycle. It monetizes its expertise by offering clients a seamless pathway from research and development through to clinical manufacturing. Clients, which range from startup biotech firms to established pharmaceutical giants, engage WuXi XDC not only for its technical prowess but also for its capacity to expedite product pipelines. By managing complex supply chains and providing robust regulatory support, the company enables its clients to reduce time-to-market, ultimately maneuvering the intricate framework of drug development with finesse. Through this strategic approach, WuXi XDC has positioned itself as a critical partner in the ADC landscape, driving innovation and delivering value to both its clientele and stakeholders.

Intrinsic Value
30.3 HKD
Overvaluation 4%
Intrinsic Value
Price
W

See Also

What is WuXi XDC Cayman Inc's Cash from Financing Activities?
Cash from Financing Activities
3.5B CNY

Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Cash from Financing Activities amounts to 3.5B CNY.

What is WuXi XDC Cayman Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
271%

Over the last year, the Cash from Financing Activities growth was 165%. The average annual Cash from Financing Activities growth rates for WuXi XDC Cayman Inc have been 271% over the past three years .

Back to Top